Product Name: CAPS1 Polyclonal Antibody, Cy7 Conjugated
Applications: IF(IHC-P)
Reactivity: Human, Mouse, Rat
Conjugation: Cy7
Host: Rabbit
Sourcr: KLH conjugated synthetic peptide derived from human CAPS1
Clonality: Polyclonal
CAS NO: 1303470-48-5
Product: N6-Cyclohexyladenosine
Isotype: IgG
Concentration: 1ug/ul
Purification: Purified by Protein A.
Storage: Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at 4°C for 12 months.
Synonyms: Cadps; CADPS1; Calcium dependent secretion activator 1; Calcium-dependent activator protein for secretion 1; Calcium-dependent secretion activator 1; Caps; CAPS-1; rCAPS; CAPS1_HUMAN.
Background: Calcium-dependent secretion activators (CAPS-1 and CAPS-2) are calcium-binding proteins that direct neurotransmitter and neuropeptide-filled vesicles to the cell membrane for secretory granule exocytosis. Both CAPS-1 and CAPS-2 are expressed primarily in the brain where they regulate the secretion of various substances. The CAPS proteins contain a PH domain that is essential for regulation of exocytosis, as well as regulation of phospholipid binding. Through their regulation of neurotrophin release from granule cells, CAPS proteins help to regulate cell fate during neuronal development. CAPS-1 is thought to regulate catecholamine release from neuronal cells, while CAPS-2 is thought to regulate release of both brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) from granule cells. Defects in the genes encoding CAPS-1 and CAPS-2 are implicated in impaired cerebral development and autism.
PubMed ID:http://jpet.aspetjournals.org/content/291/2/705
Heme Oxygenase heme-oxygenase.com
Just another WordPress site
